<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01415960</url>
  </required_header>
  <id_info>
    <org_study_id>GP/C/05/PRO</org_study_id>
    <nct_id>NCT01415960</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer</brief_title>
  <official_title>Efficacy and Safety of a New Leuprolide Acetate 22.5 mg Depot Formulation in the Treatment of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GP-Pharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GP-Pharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some patients with prostate cancer benefit from androgen deprivation therapy which reduces&#xD;
      levels of testosterone. Leuprolide is a synthetic Luteinizing hormone releasing hormone&#xD;
      (LHRH) analogue which upon administration can decrease testosterone levels to ≤0.5 ng/mL.&#xD;
      Leuprolide Acetate 22.5 mg Depot is a microencapsulated formulation of leuprolide which is&#xD;
      released slowly over time and effectively reduces testosterone levels in many patients to&#xD;
      ≤0.5 ng/mL for up to three months. In this study Leuprolide acetate 22.5 mg Depot will be&#xD;
      administered by intramuscular injection twice over a period of 6 months. The proportion of&#xD;
      patients with testosterone ≤0.5 ng/mL evaluated over a period of 168 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This in an open-label, multicenter, multiple-dose investigation of 2 doses of leuprolide&#xD;
      acetate 22.5 mg administered with a 3-month interval to patients with histologically proven&#xD;
      carcinoma of prostate who might benefit from medical androgen deprivation therapy. A total of&#xD;
      up to 160 male patients will receive their first single intramuscular injection of leuprolide&#xD;
      acetate 22.5 mg on Day 0 (after baseline assessment) and then after 3 months (Day 84). The&#xD;
      study duration will be 6 months. Thirty(30) patients will be screened per protocol and&#xD;
      enrolled at selected centers to form the PK cohort. The PK/PD analysis will be performed&#xD;
      using plasma specimens from the first 20 of 30 patients enrolled in the study (and included&#xD;
      in the PK/PD cohort). Patients not belonging to the PK cohort will be screened and enrolled&#xD;
      per protocol and will follow the same study schedule as those enrolled in the PK portion of&#xD;
      the study, except they will provide only sparse PK sampling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Chemical Castration (Defined as Testosterone Levels ≤ 0.5 ng/mL) at Days 28, 84, and 168.</measure>
    <time_frame>168 days</time_frame>
    <description>The primary endpoint was testosterone ≤ 0.5 ng/mL assessed on Days 28, 84, and 168. Thereby, maintenance of castration was to be demonstrated through Day 168 with no missing data at these key time points, unless the missing data were due to an event unrelated to the study drug (ITT patients).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of Serum Luteinizing Hormone (LH)</measure>
    <time_frame>168 days</time_frame>
    <description>For purposes of calculating summary statistics, any concentration values Below Limit of Quantification (BLQ) were to be assigned ½ the Low Limit of Quantification (LLOQ) (LLOQ=2.00). If the calculated mean, median or minimum value at a time point was less than LLOQ, &quot;BLQ&quot; is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was calculated for that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle-stimulating Hormone (FSH)</measure>
    <time_frame>168 days</time_frame>
    <description>For purposes of calculating summary statistics, any concentration values Below Limit of Quantification (BLQ) were to be assigned ½ the Low Limit of Quantification (LLOQ) (LLOQ=3.66). If the calculated mean, median or minimum value at a time point was less than LLOQ, &quot;BLQ&quot; is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was to be calculated for that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific Antigen (PSA) Concentrations</measure>
    <time_frame>168 days</time_frame>
    <description>For purposes of calculating summary statistics, any concentration values Below Limit Quantification (BLQ) were to be assigned ½ the Low Limit Quantification (LLOQ) (LLOQ=0.36). If the calculated mean, median or minimum value at a time point was less than LLOQ, &quot;BLQ&quot; is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was calculated for that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of Leuprolide Cmax</measure>
    <time_frame>Cmax1: 0, 1 and 4 hours post-dose on Day 0 and once on Days 2, 14, 28, 56; Cmax2: 0, 1 and 4 hours post-dose on Day 84 and once on Days 86, 112 and 168.</time_frame>
    <description>Leuprolide Pharmacokinetic Parameters (PK Population).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>168 Days</time_frame>
    <description>The WHO/ECOG, bone pain, urinary pain and urinary symptoms data reported are the most frequent percentage at the assessment time.&#xD;
The WHO/ECOG performance status was summarized using the 0 to 4 WHO/ECOG performance status scale. (0= fully active, able to carry on all pre-disease performances without restriction).&#xD;
Bone pain, urinary pain and urinary symptoms were determined using a 10-point scale (1= no pain/symptoms, 10= worst pain/symptom imaginable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of Leuprolide Tmax</measure>
    <time_frame>84 days</time_frame>
    <description>Leuprolide Pharmacokinetic Parameters (PK Population).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Leuprolide acetate 22.5 mg depot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leuprolide acetate 22.5 mg depot administered twice, 3 months apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide acetate 22.5 mg depot, GP-Pharm SA</intervention_name>
    <description>Administered by im injection, twice during the study, three months apart</description>
    <arm_group_label>Leuprolide acetate 22.5 mg depot</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main selection criteria:&#xD;
&#xD;
        Patients with histologically documented prostate cancer who might benefit from medical&#xD;
        androgen deprivation therapy (i.e., reduction of androgen levels) will be considered for&#xD;
        enrollment in the study if they meet the following criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Males ≥18 years of age&#xD;
&#xD;
          2. Patients with histologically documented prostate carcinoma who might benefit from&#xD;
             medical androgen deprivation therapy.&#xD;
&#xD;
          3. Life expectancy of at least 1 year.&#xD;
&#xD;
          4. WHO/ECOG performance status of 0, 1, or 2.&#xD;
&#xD;
          5. Adequate renal function at Screening as defined by serum creatinine ≤1.6 times the&#xD;
             upper limit of normal (ULN) for the clinical laboratory.&#xD;
&#xD;
          6. Adequate and stable hepatic function as defined by bilirubin ≤1.5 times the ULN and&#xD;
             transaminases (i.e., aspartate aminotransferase, alanine aminotransferase) ≤2.5 times&#xD;
             the ULN for the clinical laboratory at Screening.&#xD;
&#xD;
          7. Ability to comprehend the full nature and purpose of the study, including possible&#xD;
             risks and side effects; ability to cooperate with the investigator and to comply with&#xD;
             the requirements of the entire study.&#xD;
&#xD;
          8. Following receipt of verbal and written information about the study,the patient must&#xD;
             provide signed informed consent before any study related activity is carried out.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of brain metastases, in the opinion of the investigator, taking into account&#xD;
             medical history, clinical observations, and symptoms (rationale: to minimize&#xD;
             possibility of serious acute flare reactions that would necessitate concomitant&#xD;
             administration of other drugs).&#xD;
&#xD;
          2. Evidence of spinal cord compression, in the opinion of the investigator, taking into&#xD;
             account medical history, clinical observations, and symptoms (rationale: see rationale&#xD;
             in criterion 1).&#xD;
&#xD;
          3. Evidence of severe urinary tract obstruction with threatening urinary retention, in&#xD;
             the opinion of the investigator, taking into account medical history, clinical&#xD;
             observations, and symptoms (rationale: see rationale in criterion 1).&#xD;
&#xD;
          4. Presence of any tumor in the immediate vicinity that could cause spinal cord&#xD;
             compression, in the opinion of the investigator, taking into account medical history&#xD;
             and clinical observations (rationale: see rationale in criterion 1).&#xD;
&#xD;
          5. Excruciating, severe pain from extensive osseous deposits, taking into account medical&#xD;
             history, clinical observations, and symptoms (rationale: see rationale in criterion&#xD;
             1).&#xD;
&#xD;
          6. Testosterone levels &lt;1.5 ng/mL at Screening, This testosterone level will be locally&#xD;
             determined at the laboratory of each clinical site (rationale: to ensure that all&#xD;
             patients have normal baseline testosterone levels).&#xD;
&#xD;
          7. Previous androgen ablative therapy lasting more than 6 months, such as LHRH analogues&#xD;
             (e.g., Leuprolide acetate, Goserelin, Buserelin) or antagonists (degarelix). Also,&#xD;
             therapy must have not occurred within 12 months before the screening visit. Any prior&#xD;
             ADT must have not exceeded 6 months of therapy.&#xD;
&#xD;
          8. Previous treatment with androgen-receptor blockers, such as Bicalutamide, Flutamide,&#xD;
             Megestrol acetate, Ciproterone will only be allowed after a 3 month washout prior to&#xD;
             the screening visit (rationale: these therapies alter a patient's androgenic hormonal&#xD;
             response for a sustained period).&#xD;
&#xD;
          9. Previous orchiectomy, adrenalectomy, or hypophysectomy (no washout allowed)&#xD;
             (rationale: these therapies could have altered a patient's androgenic hormonal&#xD;
             response).&#xD;
&#xD;
         10. Previous prostatic surgery (e.g., radical prostatectomy, transurethral resection of&#xD;
             the prostate) within 2 weeks before Baseline (rationale: these therapies could have&#xD;
             altered a patient's androgenic hormonal response and/or adverse reaction profile).&#xD;
&#xD;
         11. Previous local therapy to the primary tumor with a curative attempt other than surgery&#xD;
             (external beam radiotherapy, brachytherapy, thermotherapy, cryotherapy) within 2 weeks&#xD;
             before Baseline (rationale: these therapies could have altered a patient's adverse&#xD;
             reaction profile).&#xD;
&#xD;
         12. Previous cancer systemic therapy such as chemotherapy, immunotherapy (e.g., antibody&#xD;
             therapies, tumor vaccines), biological response modifiers (e.g., cytokines).&#xD;
&#xD;
         13. Any investigational drug within 5 half-lives of its physiological action or 3 months,&#xD;
             whichever is longer, before Baseline (rationale: to prevent adverse effects of another&#xD;
             drug being attributed to study drug and to prevent potential interactions).&#xD;
&#xD;
         14. Administration of 5-α-reductase inhibitors (Finasteride, Dutasteride) within 3 months&#xD;
             before Baseline (rationale: alters PSA levels and androgen metabolism of the prostate&#xD;
             cells). Prior use of 5-α-reductase inhibitors will be allowed with a 3 month washout.&#xD;
&#xD;
         15. Over-the-counter or alternative medical therapies that have an estrogenic or&#xD;
             antiandrogenic effect (i.e., PC-SPES, saw palmetto, Glycyrrhiza, Urinozinc,&#xD;
             dehydroepiandrosterone) within the 3 months before Baseline.&#xD;
&#xD;
         16. Hematological parameters (red blood cells, total and differential white blood cell&#xD;
             count, platelet count, hemoglobin, hematocrit) outside 20% of the ULN or lower limits&#xD;
             of normal for the clinical laboratory at Screening (rationale: to render potential&#xD;
             study drug-related laboratory abnormalities easier to observe).&#xD;
&#xD;
         17. Coexistent malignancy, in the opinion of the investigator (rationale: to decrease&#xD;
             possibility of disease-caused or associated therapy-caused adverse effects being&#xD;
             attributed to study drug).&#xD;
&#xD;
         18. Uncontrolled congestive heart failure, myocardial infarction or a coronary vascular&#xD;
             procedure (e.g., balloon angioplasty, coronary artery bypass graft) or significant&#xD;
             symptomatic cardiovascular disease(s) within 6 months before Baseline; resting&#xD;
             uncontrolled hypertension (≥160/100 mm Hg) or symptomatic hypotension within 3 months&#xD;
             before Baseline (rationale: to decrease possibility of disease-caused or associated&#xD;
             therapy-caused adverse effects being attributed to study drug).&#xD;
&#xD;
         19. Venous thrombosis within 6 months of Baseline (rationale: influencing testosterone&#xD;
             levels may be associated with increased likelihood of deep venous thrombosis).&#xD;
&#xD;
         20. Uncontrolled diabetes, in the opinion of the investigator (rationale:&#xD;
&#xD;
             patients with uncontrolled diabetes need to compensate the metabolic disorder before&#xD;
             treatment with LHRH analogues).&#xD;
&#xD;
         21. History of drug and/or alcohol abuse within 6 months of Baseline (rationale: these&#xD;
             patients are likely to have numerous medical abnormalities and are unlikely to comply&#xD;
             with protocol).&#xD;
&#xD;
         22. Serious concomitant illness(es) or disease(s) (e.g., hematological, renal, hepatic,&#xD;
             respiratory, endocrine, psychiatric) that may interfere with, or put patients at&#xD;
             additional risk for, their ability to receive the treatment outlined in the protocol&#xD;
             (rationale: to decrease possibility of disease-caused or associated therapy-caused&#xD;
             adverse effects being attributed to study drug).&#xD;
&#xD;
         23. Patients on anticoagulative therapy including warfarin (Coumadin®), Dabigatran&#xD;
             Etexilate (Pradaxa®) and heparin. Those patients on low-dose, low-molecular weight&#xD;
             heparin may be enrolled in the study (rationale: to decrease possibility of&#xD;
             disease-caused or associated therapy-caused adverse effects being attributed to study&#xD;
             drug). Plavix and Aspirin are allowed for cardiac prophylaxis as long as all&#xD;
             inclusion/exclusion criteria are met concerning coagulation parameters and&#xD;
             thromboembolic history. Special care to avoid hematoma at the injection site must be&#xD;
             observed.&#xD;
&#xD;
         24. Abnormal coagulation studies (prothrombin time [PT]/partial thromboplastin time [PTT])&#xD;
             at Baseline.&#xD;
&#xD;
         25. History of serious bleeding on injections, an elevated INR, concomitant medications or&#xD;
             any other condition (i.e. significant thrombocytopenia) that in opinion of the&#xD;
             investigator would render the subject at risk of significant bleeding with injections.&#xD;
&#xD;
         26. Blood donations/losses within 2 months of Baseline, apart from previous prostatic&#xD;
             surgery patients (see exclusion 10 [rationale: to avoid excessive blood donations]).&#xD;
&#xD;
         27. Known hypersensitivity to GnRH, GnRH agonists, including any LHRH analogues, or any&#xD;
             excipients of the study formulation (rationale: to minimize hypersensitivity reaction&#xD;
             to study drug).&#xD;
&#xD;
         28. History of Immunization (within 4 weeks of Baseline) and specifically flu shots&#xD;
             (within 1 week of Baseline or 1 week before and after study drug administration)&#xD;
             (Rationale: to decrease the possibility of non treatment-related AEs being attributed&#xD;
             to study drug).&#xD;
&#xD;
         29. Skin disease that would interfere with injection site evaluation.&#xD;
&#xD;
         30. Men not willing to use appropriate birth control methods such as surgical&#xD;
             sterilization or barrier contraception or men with partners of child bearing potential&#xD;
             not willing to use appropriate birth control methods, such as surgical sterilization,&#xD;
             hormonal birth control (partner), an intrauterine device (partner) or double-barrier&#xD;
             method for the entire study period.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Genesis Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Urological Associates</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Health Team</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winter Park Urology Associates, PA</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Medical Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Idaho Urology</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Urologic Institute</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Urology</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Clinical Research</name>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Urology Associates, LLC</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urological Institute of Northeastern New York</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Urology Research Group</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Premier Medical Group of the Hudson Valley, PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staten Island Urological Research, PC</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston Salem</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants of SE PA</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Health Specialists, LLC</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates, PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Urology Research Center</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2011</study_first_posted>
  <results_first_submitted>July 23, 2015</results_first_submitted>
  <results_first_submitted_qc>November 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2017</results_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>androgen deprivation therapy.</keyword>
  <keyword>Leuprolide Acetate Depot Formulation</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>testosterone</keyword>
  <keyword>serum luteinizing hormone</keyword>
  <keyword>follicle-stimulating hormone</keyword>
  <keyword>prostate-specific antigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Leuprolide Acetate 22.5 mg Depot</title>
          <description>Leuprolide acetate 22.5 mg depot administered twice, 3 months apart&#xD;
Leuprolide acetate 22.5 mg depot, GP-Pharm SA: Administered by im injection, twice during the study, three months apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PK Subgroup</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151">Patients completed Study (151) Per protocol Patients (146)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Leuprolide Acetate 22.5 mg Depot</title>
          <description>Leuprolide acetate 22.5 mg depot administered twice, 3 months apart&#xD;
Leuprolide acetate 22.5 mg depot, GP-Pharm SA: Administered by im injection, twice during the study, three months apart</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="161"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Chemical Castration (Defined as Testosterone Levels ≤ 0.5 ng/mL) at Days 28, 84, and 168.</title>
        <description>The primary endpoint was testosterone ≤ 0.5 ng/mL assessed on Days 28, 84, and 168. Thereby, maintenance of castration was to be demonstrated through Day 168 with no missing data at these key time points, unless the missing data were due to an event unrelated to the study drug (ITT patients).</description>
        <time_frame>168 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 22.5 mg Depot</title>
            <description>Leuprolide acetate 22.5 mg depot administered twice, 3 months apart.&#xD;
Leuprolide acetate 22.5 mg depot, GP-Pharm SA: Administered by im (intramuscular) injection, twice during the study, three months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Chemical Castration (Defined as Testosterone Levels ≤ 0.5 ng/mL) at Days 28, 84, and 168.</title>
          <description>The primary endpoint was testosterone ≤ 0.5 ng/mL assessed on Days 28, 84, and 168. Thereby, maintenance of castration was to be demonstrated through Day 168 with no missing data at these key time points, unless the missing data were due to an event unrelated to the study drug (ITT patients).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="94.7" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determination of Serum Luteinizing Hormone (LH)</title>
        <description>For purposes of calculating summary statistics, any concentration values Below Limit of Quantification (BLQ) were to be assigned ½ the Low Limit of Quantification (LLOQ) (LLOQ=2.00). If the calculated mean, median or minimum value at a time point was less than LLOQ, &quot;BLQ&quot; is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was calculated for that time point.</description>
        <time_frame>168 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 22.5 mg Depot</title>
            <description>Leuprolide acetate 22.5 mg depot administered twice, 3 months apart.&#xD;
Leuprolide acetate 22.5 mg depot, GP-Pharm SA: Administered by im (intramuscular) injection, twice during the study, three months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of Serum Luteinizing Hormone (LH)</title>
          <description>For purposes of calculating summary statistics, any concentration values Below Limit of Quantification (BLQ) were to be assigned ½ the Low Limit of Quantification (LLOQ) (LLOQ=2.00). If the calculated mean, median or minimum value at a time point was less than LLOQ, &quot;BLQ&quot; is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was calculated for that time point.</description>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.24" spread="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follicle-stimulating Hormone (FSH)</title>
        <description>For purposes of calculating summary statistics, any concentration values Below Limit of Quantification (BLQ) were to be assigned ½ the Low Limit of Quantification (LLOQ) (LLOQ=3.66). If the calculated mean, median or minimum value at a time point was less than LLOQ, &quot;BLQ&quot; is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was to be calculated for that time point.</description>
        <time_frame>168 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 22.5 mg Depot</title>
            <description>Leuprolide acetate 22.5 mg depot administered twice, 3 months apart.&#xD;
Leuprolide acetate 22.5 mg depot, GP-Pharm SA: Administered by im (intramuscular) injection, twice during the study, three months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Follicle-stimulating Hormone (FSH)</title>
          <description>For purposes of calculating summary statistics, any concentration values Below Limit of Quantification (BLQ) were to be assigned ½ the Low Limit of Quantification (LLOQ) (LLOQ=3.66). If the calculated mean, median or minimum value at a time point was less than LLOQ, &quot;BLQ&quot; is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was to be calculated for that time point.</description>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.14" spread="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.80" spread="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate-specific Antigen (PSA) Concentrations</title>
        <description>For purposes of calculating summary statistics, any concentration values Below Limit Quantification (BLQ) were to be assigned ½ the Low Limit Quantification (LLOQ) (LLOQ=0.36). If the calculated mean, median or minimum value at a time point was less than LLOQ, &quot;BLQ&quot; is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was calculated for that time point.</description>
        <time_frame>168 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 22.5 mg Depot</title>
            <description>Leuprolide acetate 22.5 mg depot administered twice, 3 months apart.&#xD;
Leuprolide acetate 22.5 mg depot, GP-Pharm SA: Administered by im (intramuscular) injection, twice during the study, three months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate-specific Antigen (PSA) Concentrations</title>
          <description>For purposes of calculating summary statistics, any concentration values Below Limit Quantification (BLQ) were to be assigned ½ the Low Limit Quantification (LLOQ) (LLOQ=0.36). If the calculated mean, median or minimum value at a time point was less than LLOQ, &quot;BLQ&quot; is presented. In addition, since a high proportion of BLQ values may affect the Standard Deviation (SD); if more than 50% of values were imputed, then no mean or median was calculated for that time point.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.36" spread="165.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="10.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determination of Leuprolide Cmax</title>
        <description>Leuprolide Pharmacokinetic Parameters (PK Population).</description>
        <time_frame>Cmax1: 0, 1 and 4 hours post-dose on Day 0 and once on Days 2, 14, 28, 56; Cmax2: 0, 1 and 4 hours post-dose on Day 84 and once on Days 86, 112 and 168.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 22.5 mg Depot</title>
            <description>Leuprolide acetate 22.5 mg depot administered twice, 3 months apart.&#xD;
Leuprolide acetate 22.5 mg depot, GP-Pharm SA: Administered by im (intramuscular) injection, twice during the study, three months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of Leuprolide Cmax</title>
          <description>Leuprolide Pharmacokinetic Parameters (PK Population).</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0/Dose 1 Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.79" spread="18.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84/Dose 2 Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.30" spread="18.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoints</title>
        <description>The WHO/ECOG, bone pain, urinary pain and urinary symptoms data reported are the most frequent percentage at the assessment time.&#xD;
The WHO/ECOG performance status was summarized using the 0 to 4 WHO/ECOG performance status scale. (0= fully active, able to carry on all pre-disease performances without restriction).&#xD;
Bone pain, urinary pain and urinary symptoms were determined using a 10-point scale (1= no pain/symptoms, 10= worst pain/symptom imaginable).</description>
        <time_frame>168 Days</time_frame>
        <population>Safety endpoints adverse events (AEs), local tolerability, vital signs, performance status, bone pain, urinary pain, and urinary symptoms, occurrence of hot flushes and clinical laboratory and electrocardiogram (ECG) results.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 22.5 mg Depot</title>
            <description>Leuprolide acetate 22.5 mg depot administered twice, 3 months apart.&#xD;
Leuprolide acetate 22.5 mg depot, GP-Pharm SA: Administered by im (intramuscular) injection, twice during the study, three months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoints</title>
          <description>The WHO/ECOG, bone pain, urinary pain and urinary symptoms data reported are the most frequent percentage at the assessment time.&#xD;
The WHO/ECOG performance status was summarized using the 0 to 4 WHO/ECOG performance status scale. (0= fully active, able to carry on all pre-disease performances without restriction).&#xD;
Bone pain, urinary pain and urinary symptoms were determined using a 10-point scale (1= no pain/symptoms, 10= worst pain/symptom imaginable).</description>
          <population>Safety endpoints adverse events (AEs), local tolerability, vital signs, performance status, bone pain, urinary pain, and urinary symptoms, occurrence of hot flushes and clinical laboratory and electrocardiogram (ECG) results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline WHO/ECOG Score 0 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 168 WHO/ECOG Scores 0 (n=152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Bone Pain score 1 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 168 Bone Pain score 1 (n=152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Urinary Pain score 1 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 168 Urinary Pain Score 1 (n=152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Urinary Symptoms score 1 (n=161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 168 Urinary Symptoms score 1 (n=152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determination of Leuprolide Tmax</title>
        <description>Leuprolide Pharmacokinetic Parameters (PK Population).</description>
        <time_frame>84 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 22.5 mg Depot</title>
            <description>Leuprolide acetate 22.5 mg depot administered twice, 3 months apart.&#xD;
Leuprolide acetate 22.5 mg depot, GP-Pharm SA: Administered by im (intramuscular) injection, twice during the study, three months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of Leuprolide Tmax</title>
          <description>Leuprolide Pharmacokinetic Parameters (PK Population).</description>
          <units>day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0/Dose 1 Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84/Dose 2 Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Leuprolide Acetate 22.5 mg Depot</title>
          <description>Leuprolide acetate 22.5 mg depot administered twice, 3 months apart&#xD;
Leuprolide acetate 22.5 mg depot, GP-Pharm SA: Administered by im injection, twice during the study, three months apart</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CONGESTIVE HEART FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>INCARCERATED INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>RECTAL BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BENIGN NEOPLASM OF BLADDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>TEAE Related Injection site pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>TEAE Related Fatigue</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>TEAE Related Hot Flushes</sub_title>
                <counts group_id="E1" events="146" subjects_affected="126" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All information from the trial is property of the Sponsor and the PI has no right on it except the prior writing authorization of the sponsor</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Neal Shore MD</name_or_title>
      <organization>Grand Strand Urology Carolina Urology Reseearch Centre</organization>
      <phone>+1 843 839 1679</phone>
      <email>nshore@grandstrandurology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

